Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

No­var­tis is al­ways one of the in­dus­try’s biggest R&D spenders. As they of­ten do to­ward the end of each year, com­pa­ny ex­ecs are high­light­ing the drugs they ex­pect will most like­ly be win­ners in 2021.

And they’re al­so dream­ing about some po­ten­tial big-time lot­tery tick­ets.

As part of its an­nu­al in­vestor pre­sen­ta­tion Tues­day, where the com­pa­ny al­lows in­vestors and an­a­lysts to vir­tu­al­ly schmooze with the big­wigs, No­var­tis CEO Vas Narasimhan will out­line what he thinks are the phar­ma’s “Wild Cards.” The slate of five ex­per­i­men­tal drugs are those that No­var­tis hopes can be high-risk, high-re­ward en­trants in­to the mar­ket over the next half-decade or so, and cov­er a wide range of in­di­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.